UBS has reaffirmed its Buy rating for Novartis, setting a price target of 111 francs, following insights from a recent conference. CFO Harry Kirsch expressed optimism about growth prospects for 2025, coinciding with the expiration of the Entresto patent, according to analyst Matthew Weston.
UBS has maintained its 'Buy' rating for Novartis, setting a price target of 111 francs. CFO Harry Kirsch expressed optimism about the company's growth prospects for 2025, coinciding with the expiration of the Entresto patent, according to analyst Matthew Weston.
UBS has maintained its "Buy" rating for Novartis, setting a price target of 111 francs, following insights from a recent conference. CFO Harry Kirsch expressed optimism about growth prospects for 2025, coinciding with the expiration of the Entresto patent, according to analyst Matthew Weston.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.
